Navigation Links
Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
Date:11/9/2010

ific body systems after treatment with epratuzumab.  Improvements were particularly prominent in cardiorespiratory and neuropsychiatric systems in which symptom improvements are often difficult to achieve.

These results demonstrated that in a patient population with predominantly high or severe disease activity, differences in responder rates between the epratuzumab 600mg weekly and 1200mg every other week groups, and the placebo group was observed as early as week 12, with the emergence of improvements apparent in week 8.

In two previous phase II randomized controlled trials, epratuzumab treatment resulted in clinically meaningful reduced disease activity, improved health-related quality of life (HRQoL) measurements and reduced reliance on corticosteroids compared to placebo treatment in patients with active moderate and severe SLE.

"We are pleased by the repeated consistency of symptom improvement demonstrated by epratuzumab in all our clinical studies to date and we look forward to confirming these results in our phase 3 studies due to start later this year," said Prof. Dr. Iris Loew-Friedrich, Chief Medical Officer of UCB. She added, "Achieving a BILAG improvement, especially at an early timepoint seen in EMBLEM™, is a hopeful sign of the drug's future potential."

Epratuzumab is a humanized monoclonal antibody targeting CD22 and modulating B cell activity.  Although the exact role of CD22 is not fully understood, it is considered to be a regulator of B cell function. B cells are known to contribute to SLE by producing antibodies against the body's own cells and tissues, causing the immune system to turn on itself, resulting in inflammation and tissue damage. Epratuzumab is an anti-B-cell therapeutic, because of its ability to modulate B cell function without depleting a large portion of these lymphocytes.

* This study was not powered to detect statistical differences between treatment arms (p values were no
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 Z-Medica, a ... it has launched the first-ever line of products designed ... The line includes QuikClot ® EMS 4x4 Dressing, ... ® EMS Rolled Gauze™, all custom-designed to help ... they can be transported to a hospital or trauma ...
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... , May 22, 2013 Hemoglobin A1C ... patients with Type 2 diabetes, while modest improvements ... health outcomes and can lead to substantial healthcare ... the International Society for Pharmacoeconomics and Outcomes Research ... two studies, sponsored by Valeritas, makers of the ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... 21, 2011  BARRX Medical Inc., a leader in developing ... to remove precancerous tissue from the gastrointestinal tract, announces ... be acquired by Covidien.  Covidien is a leading global ... advanced energy-based devices.  Covidien will acquire ...
... NORRITON, Pa., Nov. 21, 2011 Tengion, Inc. (NASDAQ: ... today announced that Brian Davis, Vice President Finance and ... upcoming Piper Jaffray 23rd Annual Health Care Conference on ... A live audio webcast of the presentation ...
Cached Medicine Technology:BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:5/22/2013)... Today, Zane Benefits, Inc. published a ... . Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution plans and health ... beginning in 2014 as part of the Affordable Care ... businesses will become available through new state health insurance ...
(Date:5/22/2013)... hospitals may be reaping enormous income for patients ... infections contracted in their intensive care units. , ... the American Journal of Medical Quality , ... develops an avoidable central line-associated bloodstream infection (CLABSI) ... than a similar infection-free patient. Moreover, hospitals earn ...
(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science ... sharing a recipe for making energy bars at home. , ... ,” takes a recipe modified from one recently featured ... day it gets more and more difficult to understand what ... size of the nutrition label continues to grow and consumers ...
(Date:5/22/2013)... WI (PRWEB) May 22, 2013 Unknown to ... their area at 30 mph. Minutes before it struck, ... of the nearing threat. This gave them time to reach ... & Data is proud to provide a product that ... occurs. A Wheelock SAFEPATH® SP40S Emergency Evacuation System ...
(Date:5/22/2013)... with heart failure are more likely to experience poorer ... mildly underactive, according to a new study. ... risk of death linked to the condition, which is ... first to show that African-Americans who have hypothyroidism face ... racial and ethnic groups," Dr. Connie Rhee, of Brigham ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2Health News:Underactive Thyroid and Heart Failure a Bad Combination: Study 2
... it will open its first spa this autumn in Japan, ... ,The Armani Group is opening its giant ... part of its strategy to lure customers in Japan, already ... square-foot) complex opening on November 8 will include a spa ...
... minister on Wednesday lamented opposition from several states to a ... report said . ,"In our country, we do ... that is why we have a billion population," Health Minister ... Day. ,"In our close-knit society, we have to ...
... foods protect against the clustering of abnormal body chemistry known ... Journal of Epidemiology and Community Health. ,The syndrome has ... disease, and premature death. ,The findings are based ... and 59, all of whom were part of a long ...
... the more number of blemishes or moles you have, the slower you ... compared key ageing DNA with the number of moles in a study ... found that the more moles a person had, the more likely their ... for the spotted to rejoice, as this is in spite of the ...
... in London are long overdue but it is unclear how ... improve patient care in the capital , BMA leaders claim. ... Council, said: There is a case for changing how some ... of these proposals may not be in the best interests ...
... MP3s in a storm can literally blow your brains out as ... . ,Most people who are struck by lightning are not ... jumps from the object that was hit. ,In 2006, ... a side flash from a tree that had been struck. ...
Cached Medicine News:Health News:Dotted All Over? - Count Yourself Lucky 2Health News:Polyclinics Could Threaten NHS Services, Warns BMA 2
... of the Robot Stainer HMS 760 X ... automatically lifted and transferred during program execution. ... drip preventing system contributes to a significant ... An acrylic glass cover and a vapor ...
... The Bright Starlet is the world's smallest cryostat! ... with a choice of handwheel or lever operation. ... easy-to-clean and resist common decontaminating agents. An insulated ... the refrigeration system and to reduce frosting when ...
... The Leica TP1020 product family are semi-enclosed ... perfect combination of approved technology with modern ... and maximum safety for tissues at all ... design based on proven precision mechanics in ...
... in a power assisted microtome combines the ... assisted horizontal movements are proportionally related to ... edge. Duplicate controls provide for convenient operation ... the operating levers and handles may be ...
Medicine Products: